SPECT/CT, PET/CT, and PET/MRI for Response Assessment of Bone Metastases.

Gary Cook, Nazanin Zamani-Siahkali, Ghasemali Divband, Christian Pirich, Mohsen Beheshti, Seyed Ali Mirshahvalad, Patrick Veit-Haibach, Abolfazl Farbod

Journal: Seminars in nuclear medicine 2024;54(3):356-370

PMID: 38172001

Free Full Text on Elsevier Science View on PubMed

Abstract

Recent developments in hybrid SPECT/CT systems and the use of cadmium-zinc-telluride (CZT) detectors have improved the diagnostic accuracy of bone scintigraphy. These advancements have paved the way for novel quantitative approaches to accurate and reproducible treatment monitoring of bone metastases. PET/CT imaging using [F]F-FDG and [F]F-NaF have shown promising clinical utility in bone metastases assessment and monitoring response to therapy and prediction of treatment response in a broad range of malignancies. Additionally, specific tumor-targeting tracers like [Tc]Tc-PSMA, [Ga]Ga-PSMA, or [C]C- or [F]F-Choline revealed high diagnostic performance for early assessment and prognostication of bone metastases, particularly in prostate cancer. PET/MRI appears highly accurate imaging modality, but has associated limitations notably, limited availability, more complex logistics and high installation costs. Advances in artificial intelligence (Al) seem to improve the accuracy of imaging modalities and provide an assistant role in the evaluation of treatment response of bone metastases.

Address: Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, University Hospital, Paracelsus Medical University, Salzburg, Austria; Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran.; Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, University Hospital, Paracelsus Medical University, Salzburg, Austria; Joint Department of Medical Imaging, University Medical Imaging Toronto, University Health Network, Sinai Health System, Women's College Hospital, University of Toronto, Toronto, Canada.; Department of Nuclear Medicine, Jam Hospital, Tehran, Iran.; Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, University Hospital, Paracelsus Medical University, Salzburg, Austria.; Joint Department of Medical Imaging, University Medical Imaging Toronto, University Health Network, Sinai Health System, Women's College Hospital, University of Toronto, Toronto, Canada.; Cancer Imaging Department, School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.; Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, University Hospital, Paracelsus Medical University, Salzburg, Austria. Electronic address: [email protected].

DOI: 10.1053/j.semnuclmed.2023.11.005